Moderna, Inc. (MRNA) Down 19.1% — Time to Throw in the Towel?
Moderna, Inc. (MRNA) suffered a brutal reversal on Thursday, surrendering $33.36 per share and closing at $141.02 on the NASDAQ. The session's decline came just one day after the stock set a fresh 52-week high of $176.66 on August 19, 2026 — meaning MRNA has already given back nearly all of its record-breaking gains and now sits approximately 20.2% below that peak. The stock's 52-week range of $22.28 to $176.66 tells the story of a deeply volatile name, and Thursday's collapse is the latest reminder of how quickly sentiment can shift.
Volume on Thursday was extraordinary, with roughly 39.3 million shares changing hands — more than four times the 90-day average of approximately 9.3 million. That kind of volume on a sharp down day signals widespread selling pressure, not a calm rotation. The magnitude of turnover relative to the average confirms this was a broad-based exit, not a quiet drift lower.
Why Moderna, Inc. Price is Moving Lower
Thursday's decline is a textbook case of post-catalyst profit-taking following an extreme one-session run. On August 19, the stock surged 176.97% to close at $174.38 after Moderna (MRNA) and Merck (MRK) announced that their personalized cancer vaccine, intismeran autogene, met both primary endpoints in the Phase 3 INTerpath-001 trial. The study enrolled 1,137 patients with surgically removed, high-risk stage IIB-IV melanoma and demonstrated that the vaccine combined with Merck's Keytruda meaningfully reduced the risk of melanoma returning and spreading compared with Keytruda alone — a clinically significant result. No new safety signals emerged from the trial data. Critically, there was no negative update to the trial result overnight; the selloff on August 20 reflects investors locking in gains after a near-tripling of the share price in a single session, not any deterioration in the science.
Analyst reactions reinforced the cautious tone. UBS raised its price target to $150 from $50 but maintained a Neutral rating; Jefferies lifted its target to $150 from $60 while keeping a Hold; and Piper Sandler moved its target to $167 from $77, retaining an Overweight but stopping short of an outright bullish call. Notably, all three of those revised targets remain below the prior close of $174.38, which itself signaled that even the most optimistic revised view from this group did not justify the post-announcement price. The absence of overall-survival data from the INTerpath-001 trial is a meaningful gap that tempers enthusiasm, as regulators and long-term investors typically want that endpoint before drawing firm conclusions about a therapy's durable value.
The underlying business backdrop adds further reason for caution. Moderna's most recently reported quarter ending June 30, 2026 showed revenue of just $94 million, down sharply from $352 million in the prior quarter — a sequential decline of 73.3%. For Q2 2026 reported on July 31, total revenue came in at $145 million against an expected $103 million, representing only 2.1% year-over-year growth, while GAAP EPS was a loss of $1.97, better than the $2.03 loss expected but still deeply negative. Management reiterated up to 10% full-year 2026 revenue growth and improved its expense outlook by approximately $200 million, but those incremental positives have done little to change the structural profitability picture. The next scheduled catalyst is Q3 earnings, currently estimated for November 5, 2026.
What is the Moderna, Inc. Rating - Should I Sell?
Weiss Ratings assigns MRNA a D- rating. The rating was upgraded on 3/12/2026. Current recommendation is Sell.
The fundamental picture behind that D- rating is difficult to look past. Moderna's profit margin stands at -141.42%, reflecting a company that continues to spend dramatically more than it earns as it funds a broad pipeline beyond its core COVID franchise. That figure earns the Very Weak Efficiency Index — a level that signals the business is not yet translating its scientific progress into financial returns at any meaningful scale. The forward P/E of -21.84 underscores the problem: there are no earnings on the horizon to anchor a traditional valuation. Revenue growth of just 2.11% earns a Fair Growth Index rating, suggesting the top line has stabilized from its post-COVID collapse but has not yet found a new engine of meaningful acceleration. The Weak Total Return Index and Weak Volatility Index round out the picture of a stock that has delivered poor risk-adjusted returns and is prone to violent price swings — Thursday's 19% single-day decline being a sharp illustration of the latter.
The one constructive element in the sub-index profile is the Excellent Solvency Index, which reflects Moderna's cash-heavy balance sheet — a genuine asset for a pre-profitability biotech that still needs to fund clinical trials, manufacturing scale-up, and operating losses. That financial cushion buys time, but it does not resolve the core tension between Moderna's spending rate and its current revenue base. For Weiss Ratings, balance sheet strength alone is insufficient to offset the combination of deeply negative margins, weak returns, and elevated share-price volatility.
Within the Health Care sector, Moderna ranks comparably or worse than Chugai Pharmaceutical Co., Ltd. (CHGCF, D) and Zoetis Inc. (ZTS, D), and sits alongside Natera, Inc. (NTRA, D-), Revolution Medicines, Inc. (RVMD, D-), and BeOne Medicines AG (ONC, D-). That peer grouping underscores that the D- is not an outlier call — it reflects a cohort of Health Care names where Weiss Ratings sees meaningful risk that the investment thesis has not yet been validated by durable financial results.
About Moderna, Inc.
Moderna, Inc. (MRNA) is a Health Care biotechnology company headquartered in Cambridge, Massachusetts, built around the development and commercialization of messenger RNA medicines across a broad range of disease areas. The company's commercial foundation remains its respiratory vaccine franchise, anchored by Spikevax and mNEXSPIKE for COVID-19 alongside mRESVIA for RSV, and extending into seasonal influenza, combination vaccines, and pandemic preparedness products. These programs leveraged Moderna's proprietary mRNA platform to achieve rapid development timelines and manufacturing scalability that traditional vaccine approaches cannot easily match.
Beyond respiratory diseases, Moderna has deployed its mRNA platform into latent virus vaccines targeting cytomegalovirus, Epstein-Barr virus, and HIV, as well as public health programs covering Zika, Nipah, and Mpox. The oncology pipeline has become an increasingly central part of the company's long-term narrative, led by intismeran autogene — the personalized cancer vaccine developed in collaboration with Merck — along with cancer antigen therapy, T-cell engager programs, and cell therapy enhancers. Moderna also maintains a rare disease portfolio addressing conditions such as propionic acidemia, methylmalonic acidemia, and cystic fibrosis. The company's mRNA technology generates a sequence-specific immune or protein response, meaning each program can be customized at the molecular level in ways that are difficult to replicate with conventional biologics.
Strategic alliances form a critical layer of Moderna's competitive positioning. Its collaboration with Merck & Co. is the most prominent, particularly as intismeran autogene advances through late-stage development. Additional partnerships span Vertex Pharmaceuticals for rare disease programs, immatics N.V. for cancer immunotherapy, the Bill & Melinda Gates Foundation for global health applications, and OpenAI for data and technology initiatives. These relationships provide both financial support and validation for Moderna's platform, while helping distribute development risk across a pipeline that spans multiple disease areas and therapeutic modalities simultaneously.
Investor Outlook
Moderna, Inc. (MRNA) carries a Weiss Rating of D- (Sell), reflecting a risk profile that remains elevated even after the genuine clinical progress signaled by the INTerpath-001 trial results. In the near term, investors will be watching whether the stock can find stable footing following Thursday's sharp reversal, what additional analyst commentary emerges around the intismeran autogene data package, and whether Q3 earnings on November 5 can demonstrate meaningful progress toward profitability. See full rankings of all D--rated Health Care stocks inside the Weiss Stock Screener.
--